New hope for rare cancer: experimental combo targets angiosarcoma
NCT ID NCT06898970
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests a new drug combination (vusolimogene oderparepvec plus pembrolizumab) in 18 adults with advanced angiosarcoma, a rare cancer of blood vessels. Participants must have already tried immunotherapy without success. The goal is to see if the treatment is safe and can shrink tumors. This is an early-phase trial, so the main focus is on safety and initial signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.